MHCテトラマー 製品詳細情報

Code No. TS-M014-1
T-Select HLA-A*24:02 modified WT1 Tetramer-CYTWNQMNL-PE
価格(税別) ¥209,000
包装 50 tests
在庫 0
(お問合せ）
（2024/04/20 17:00時点）
分類 Class I
生物種 Human
項目 cancer
標識 PE
免疫原（抗原） modified WT1
配列 CYTWNQMNL
MHC Allele A*24:02
位置 235-243
保存温度 4°C
メーカー MBL
関連製品 TS-M140-1 HLA-A*02:01 WT137-45 Tetramer-VLDFAPPGA-PE
TS-M140-2 HLA-A*02:01 WT137-45 Tetramer-VLDFAPPGA-APC
製品カテゴリー 分野:免疫
ツール:MHCテトラマー
使用文献
  1. Saitoh A et al. WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. Med Oncol. 28, 219-230 (2011)(PMID:20107936)
  1. Chiba Y et al. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Jpn J Clin Oncol. 40, 395-403 (2010)(PMID:20364021)
  1. Narita M et al. WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int J Med Sci. 7, 72-81 (2010)(PMID:20428337)
  1. Tsuboi A et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol. 86, 414-417 (2007)(PMID:18192109)
  1. Najima Y et al. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood. 127,722-34(2016)(PMID:26702062)
  1. Nishida S et al. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study. Cancer Immunol Res. (2018) In press.(PMID:29358173)
  1. Yanagisawa R et al. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. Anticancer Res. 38, 2217-2225 (2018)(PMID:29599342)
  1. Matsuda T et al. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. Oncol Lett. 16, 1348-1356 (2018)(PMID:29963201)
  1. Watanabe K et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci. 110, 40-51 (2019)(PMID:30375705)
  1. Morimoto S et al. Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity. Oncotarget 9, 34132-34141 (2018)(PMID:30344927)
  1. Zhang W et al. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunol Immunother.68, 121-130 (2019)(PMID:30306202)
  1. Tsuboi A et al. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunol Immunother. 68, 331-340 (2019)(PMID:30430205)
  1. Nishida S et al. Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments. Medicine (Baltimore) 98, e16771 (2019)(PMID:31415377)
  1. Nagai K et al. Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial. Anticancer Res. 40, 5765-5776 (2020)(PMID:32988904)

※在庫につきましては2024年04月20日 17時00分時点における在庫数を表示してあります。
※価格の赤色表示につきましては、キャンペーン価格の表示となっております。
※このサイトからは直接注文はできません。ご注意ください。
※保存温度の表記について： RT: 室温
※本サイトの掲載製品は、品質改良のため予告なく仕様などの変更、または販売中止となる場合がございます。あらかじめご了承ください。

MBLCopyright (C)2015 Medical ＆ Biological Laboratories Co., Ltd. All Rights Reserve